PreveCeutical Medical Inc. (CSE:PREV)

PreveCeutical Medical Income Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	2.27	0.58	0.68	0.57	0.68
Research & Development	0.23	0.08	0.09	0.08	0.06
Amortization of Goodwill & Intangibles	0.01	0.01	0.01	0.01	0.01
Operating Expenses	3.24	0.75	0.92	1.04	0.83
Operating Income	-3.24	-0.75	-0.92	-1.04	-0.83
Interest Expense	-0.32	-0.33	-0.31	-0.24	-0.47
Earnings From Equity Investments	-0.02	-	-	-	-
Currency Exchange Gain (Loss)	0	-0.04	-0	-0	-0.21
Other Non Operating Income (Expenses)	-0.12	-0.06	-0.05	-0.06	-0.06
EBT Excluding Unusual Items	-3.7	-1.17	-1.27	-1.34	-1.58
Gain (Loss) on Sale of Assets	2.01	-	-	0	-0
Other Unusual Items	-	-	-	-0.15	-0.17
Pretax Income	-1.69	-1.17	-1.27	-1.48	-1.75
Income Tax Expense	-	-	-	-	-0.02
Earnings From Continuing Operations	-1.69	-1.17	-1.27	-1.48	-1.73
Minority Interest in Earnings	0.11	-	-	-	-
Net Income	-1.58	-1.17	-1.27	-1.48	-1.73
Net Income to Common	-1.58	-1.17	-1.27	-1.48	-1.73
Shares Outstanding (Basic)	569	536	535	522	508
Shares Outstanding (Diluted)	569	536	535	522	508
Shares Change (YoY)	6.13%	0.15%	2.59%	2.72%	11.43%
EPS (Basic)	-0.00	-0.00	-0.00	-0.00	-0.00
EPS (Diluted)	-0.00	-0.00	-0.00	-0.00	-0.00
Free Cash Flow	-1.72	-0.43	-0.3	-0.22	-0.43
Free Cash Flow Per Share	-0.00	-0.00	-0.00	-	-0.00
EBITDA	-3.23	-0.74	-0.91	-1.03	-0.83
D&A For EBITDA	0.01	0.01	0.01	0.01	0.01
EBIT	-3.24	-0.75	-0.92	-1.04	-0.83

Source: S&P Global Market Intelligence. Standard template. Financial Sources.